What is Vaxcyte, Inc. (PCVX) stock price today?

Vaxcyte, Inc. (PCVX) is currently trading at $71.38, up 9.79% today.

What is PCVX P/E ratio?

Vaxcyte, Inc.'s P/E ratio is -7.42. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PCVX return on equity (ROE)?

Vaxcyte, Inc.'s return on equity (ROE) is -37.57%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Vaxcyte, Inc.'s market cap?

Vaxcyte, Inc. has a market capitalization of $10.31B.

NASDAQ · Biotechnology

Vaxcyte, Inc. (PCVX) Stock

$71.38 +9.79% NASDAQ: PCVX Healthcare

Valuation

Metric	Value
Price	$71.38
Market Cap	$10.31B
P/E Ratio	-7.42
P/B Ratio	2.97
P/S Ratio	0.00
EPS (TTM)	$-5.63
52-Week High	$79.13
52-Week Low	$36.15
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-37.57%
ROA	-33.91%
ROCE	-40.65%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.04
Current Ratio	7.90

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-104.0M	$-232.0M	$-468.0M	$-570.0M	$-924.0M
Net Profit	$-100.0M	$-223.0M	$-402.0M	$-464.0M	$-767.0M
EPS	$-1.93	$-3.44	$-4.14	$-3.80	$-5.63
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$324.0M	$1.0B	$1.4B	$3.5B	$3.0B
Total Liabilities	$40.0M	$53.0M	$167.0M	$205.0M	$360.0M
Cash	$69.0M	$835.0M	$397.0M	$388.0M	$174.0M
Borrowings	$17.0M	$18.0M	$29.0M	$71.0M	$229.0M

Latest News

Vaxcyte to Participate in Upcoming Investor Conferences GlobeNewswire · Jul 8, 2026 Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now Insider Monkey · Jul 3, 2026 Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing MT Newswires · Jun 29, 2026 Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine Insider Monkey · Jun 22, 2026 Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing MT Newswires · Jun 22, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-121.0M	$-171.0M	$-297.0M	$-453.0M	$-656.0M
Investing Cash Flow	$-219.0M	$69.0M	$-841.0M	$-2.0B	$424.0M
Financing Cash Flow	$4.0M	$5.0M	$4.0M	$13.0M	$-11.0M
Net Cash Flow	$-316.0M	$766.0M	$-437.0M	$-9.0M	$-214.0M
Free Cash Flow	$-128.0M	$-176.0M	$-365.0M	$-475.0M	$-669.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.15
EV / EBITDA	-7.72
FCF Yield	-14.69%
Quick Ratio	5.72
Interest Coverage	0.00
Return 1Y	69.99%
Return 3Y	43.42%
Return 5Y	167.76%

Ownership

Insiders Held0.50%

Institutions Held113.92%

Institutions Float Held114.49%

Institutional Holder	Shares	Report Date
Janus Henderson Group PLC	16,575,875	2026-03-31
FMR, LLC	16,492,861	2026-03-31
T. Rowe Price Investment Management, Inc.	12,126,017	2026-03-31
RA Capital Management, L.P.	11,474,599	2026-03-31
Blackrock Inc.	10,971,816	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ARCTArcturus Therapeutics Holdings Inc.	$13.74	+6.76%	-3.91	$390.53M	0.00%
EVAXEvaxion Biotech A/S	$3.05	+0.66%	-1.99	$19.27M	0.00%
GOVXGeoVax Labs, Inc.	$0.28	-1.95%	-0.02	$2.07M	0.00%
GSKGSK plc	$51.58	—	9.28	$103.73B	3.49%
IBRXImmunityBio, Inc.	$10.51	+6.05%	-10.01	$11.01B	0.00%

About Vaxcyte, Inc.

Vaxcyte, Inc. is led by CEO Grant E. Pickering, employs 507 people, headquartered in San Carlos, US, publicly traded since 2020.

Vaxcyte, Inc. (PCVX) stock trades at $71.38 with a market capitalization of $10.31B. The stock is valued at a price-to-earnings (P/E) ratio of -7.42, price-to-book of 2.97, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $36.15 and $79.13, and currently trades 9.8% below its 52-week high.

On profitability, Vaxcyte, Inc. generates a return on equity (ROE) of -37.57%, return on capital employed of -40.65%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides